pavinetant   Click here for help

GtoPdb Ligand ID: 5775

Synonyms: AZD-2624 | AZD4901 | MLE4901
Compound class: Synthetic organic
Comment: Pavinetant (AZD2624) is an orally active antagonist of neurokinin receptor 3 (TACR3) developed initially by AstraZeneca as a potential therapeutic for schizophrenia. This compound was included in AstaZeneca's Open Innovation Pharmacology Toolbox (but has since been removed). Later renamed to AZD4901 it was acquired by Millendo Therapeutics who gave it a new research code of MLE4901 for their development programs for polycystic ovary syndrome and menopausal hot flushes. A successful Phase 2 study for the latter indication was reported in April 2017 [5]. A total of eight analogues are disclosed in the AstraZeneca composition of matter filing [6],
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 96.54
Molecular weight 459.16
XLogP 5.82
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CCC(c1ccccc1)NC(=O)c1c(NS(=O)(=O)C)c(nc2c1cccc2)c1ccccc1
Isomeric SMILES CC[C@@H](c1ccccc1)NC(=O)c1c(NS(=O)(=O)C)c(nc2c1cccc2)c1ccccc1
InChI InChI=1S/C26H25N3O3S/c1-3-21(18-12-6-4-7-13-18)28-26(30)23-20-16-10-11-17-22(20)27-24(19-14-8-5-9-15-19)25(23)29-33(2,31)32/h4-17,21,29H,3H2,1-2H3,(H,28,30)/t21-/m0/s1
InChI Key QYTBBBAHNIWFOD-NRFANRHFSA-N
No information available.
Summary of Clinical Use Click here for help
As AZD2624 the compound failed in a schizophrenia proof-of-principle study [3] (see NCT00686998). A trial of AZD4901 for polycystic ovary syndrome (PCOS) was reported in 2016 [2] (see NCT01872078). As MLE4901 this compound has completed Phase 2 clinical trial for management of menopausal hot flushes [5]. MLE4901 was found to be safe and effective in this trial (see NCT02668185). A Phase 2 study for the treatment of PCOS (NCT02865915) was terminated because the risk/benefit profile did not warrant continued development.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02668185 Neuropeptide Treatment for Hot Flushes During the Menopause Phase 2 Interventional Imperial College London 4-5
NCT00686998 Phase IIA Study in Patients With Schizophrenia Phase 2 Interventional AstraZeneca
NCT01872078 A Study of AZD4901 in Females With Polycystic Ovary Syndrome Phase 2 Interventional AstraZeneca
NCT02865915 MLE4901 vs. Placebo for the Treatment of PCOS Phase 2 Interventional Millendo Therapeutics, Inc.